Mother’s Day Breakfast 2025

Laughter & tears—much like the weather—defined the 2025 Mother’s Day Breakfast, held in support of sarcoma research and patient care.

Despite the gathering grey clouds, Sydney Harbour sparkled as guests arrived at the stunning Park Hyatt Sydney. As always, the exceptional team at PHS, led by Aoife Burns and Christine Haddad, ensured every detail was immaculate. A special thanks goes to Sophie, whose long-standing involvement has guaranteed the perfect finishing touches each year.

The Guest Room looked resplendent, bathed in filtered sunlight that danced across centrepieces of sweet pink rosebuds and gypsophila, generously donated by the Lynch family. Guests were also treated to gifts from our loyal and generous sponsors—Taylors Wines, Lindt Master Chocolatier and Glasshouse —who have stood by us year after year with unwavering support.

For the past seven years, the wonderful Gloria Gapes and Dyan Comino have been pillars of unwavering support for this event. Once again, they arrived at dawn—alongside the fabulous Naomi Chun who always puts her hand up to help—to dress tables and transform the room into something truly resplendent.

The morning opened with a warm and heartfelt welcome from our former Chairman and High Court Judge, the Hon. Justice Robert Beech-Jones. This was followed by the incomparable renowned media commentator, Melissa Hoyer, whose professionalism and enduring support of CRBF leaves our family deeply touched.  This was especially poignant this year, as Melissa had only recently been discharged from an extended hospital stay—an inspiring testament to her unwavering dedication and passion for the cause.

A moving tribute then honoured those we have lost over the past year, accompanied by a soul-stirring rendition of “I Will Always Love You,” performed by Luxe Strings and the extraordinary talents of Zenith Chae, Eliza Bennett, and Nataliya Lukich.

Mitchell Rice-Brading hosted a special conversation with Suzie Carlon and Neil Gibson. The Gibson family, including children Harry and Lily, have walked this road beside our own family for many years. Their beloved Jack—former CRBF Patient Advocate—lost his life to sarcoma in 2022, changing their lives and ours forever.

In just two short years, the Gibson family has raised over half a million dollars in Jack’s memory to support sarcoma patients through the programme that now bears his name. Suzie and Neil spoke passionately about their vision to create a self-funded, sustainable model for the Jack Gibson Sarcoma Patient & Family Support Programme. The family has over many years generously offered their magnificent Manning River property, Mansfield on the Manning, for both patient respite and CRBF fundraising.

Guests then savoured a sumptuous Park Hyatt breakfast, accompanied by the sublime sounds of Luxe Strings weaving through the morning air.

The forum that followed featured the extraordinary Dreverman family. Claudia, Graham, and Judy Dreverman have all been touched by sarcoma. Claudia was a young mother when her husband Andrew, son of Judy and Graham, was diagnosed and tragically passed away. Since Andrew’s passing, the Drevermans have worked tirelessly for over a decade to raise funds and awareness, offering their magnificent country property Somerton Ridge for auctions, raffles, and as a haven for patients and families in need.

Joining them on stage was a young woman who can only be described as a force of nature, Cassandra Prothero, Gala Director of Tour de Cure. A dynamic young mother and powerhouse, Cass leads a team that generates over $4 million annually for cancer research in Australia. She outlined the organisation’s mission, its impact to date, and its growing commitment to sarcoma research.

Cass’s parents, Dominic and Andrew Robinson, have enjoyed a lifelong friendship with the Dreverman family, further strengthening the connection between Tour de Cure and our shared mission.

Completing this inspiring panel was Dr. Maya Kansara, one of the world’s leading sarcoma researchers. She spoke about the transformative impact of Tour de Cure funding and the Tom Hardyman Sarcoma Research Fund on the MoST CaSP/Sarc programme—a national initiative she leads to improve outcomes for sarcoma patients.

The mood then lightened as Mitch Rice-Brading took to the floor, microphone in hand. No one was safe. He playfully called out our former Chair Jeremy Sutcliffe, only to be quickly outwitted when Mitch referenced his cricketing days at Sydney Grammar. Mitch also made his way around the room with humorous nods to our esteemed bone tumour surgeons, Drs. Maurice Guzman and Richard Boyle, together with CRBF fundraiser/Cooper’s friend Matt Jones, to name but a few.

Raffle time followed, with the exquisite @Autore South Sea pearl earrings going to the very deserving Judy Dreverman.  Cass Prothero walked away with the magnificent Tahitian pearl earrings donated by the Rutherford family, of Rutherford Fine Jewellery & Pearls in Collins St, Melbourne.   A full list of the eight lucky winners is available at raffletix.com.au.

Book buyers were gifted a beautiful mini candle from Candles by Ange—gorgeous, hand-poured creations by the talented Ange Wanford. We are truly grateful for her ongoing love, generosity, and unwavering support.

The event concluded with closing remarks from Jeremy Sutcliffe, delivered with the grace and wit for which he’s known. A typo in the programme saw him referred to as Chairman of James Hardie, rather than his correct role as Chair of CSR, among other esteemed board appointments. Jeremy—our inaugural Chair—laid the foundations on which CRBF’s success is built. We’re grateful for his leadership, his humour, and his good-natured response. And yes, Jeremy—we’ve dismissed the research team responsible for the typo and offer our unreserved apologies.

This event is not possible without our outstanding donors and sponsors (alphabetically)

Autore Pearls

Bistro Rex

Candles by Ange 

Glasshouse & The Sapphire Group

Macleay St Bistro

Park Hyatt Sydney

Rutherford Fine Jewellery & Pearls

Steven Khalil

Taylors Wines

The Lynch Family

The Macleay Group

The Magiros Family

The Melki Family

Special thanks to Hanna and Luxe Strings for the exquisite string recital; Jarrad Sapsford who once more went over and beyond to help us behind the scenes despite not performing this year, and to the Jarrad’s mother Simonne and her wonderful friends Anita, Ami, Julie Goyen, Kathy, and Nada who each year loyally support this event.

We are deeply grateful to Stef and Mitchell O’Connor—the talented husband-and-wife duo behind Qantum Haus—who so generously gave their time and expertise to capture the essence of the event through their exquisite photography and videography.

It’s now 361 days to go until we do it all again.  We look forward to welcoming you all next year…

MoST/CaSP Sarc Programme Launch


We are thrilled to share a significant milestone in the mission to end sarcoma. CRBF, in collaboration with the Tom Hardyman Sarcoma Research Fund and Tour de Cure Spring Lunch—on behalf of the Andrew Dreverman Legacy for Sarcoma Research Fund—has proudly co-funded groundbreaking research that has led to the launch of a new sarcoma-focused programme through Omico Australia.

In November 2023, the Tour de Cure Spring Lunch raised an incredible $1.3 million in just four hours—an outstanding achievement. The beneficiaries included CRBF and, most importantly, the sarcoma community, alongside funding for onco-fertility support for young patients at the Royal Women’s Hospital Sydney.  The Spring Lunch showcases the incredible work of a remarkable team, together with Dominique Robinson, her daughter Cassandra Prothero and Dom’s bother Bruno Maurel, OAM.

On Sunday February 16, the MoST/CaSP/Sarc programme was officially launched and will exist under the leadership of Professor David Thomas and Dr. Maya Kansara. We are beyond grateful to them and to their team for the work they have placed into this pivotal programme.

Expected to be the largest of its kind globally, this programme will encompass a cohort of over 3,000 patients with international reach—an essential step forward in advancing sarcoma research and treatment.

Special thanks to Phil Baker the CRBF Media and PR Consultant who volunteers his expertise to bring these stories together.

Press Release - draft document for unsw:omico

International Childhood Cancer Day

 

At CRBF, we firmly believe that hope lies in research, and we are fortunate to have some of the world’s leading experts right here in Australia.

Over the past 12 months, we have been proud to co-fund the following innovative paediatric and AYA research projects.

CaSP Sarc Programme – Omico Australia UNSW

We are excited to announce the launch of  the MoST/CASP-SARC Initiative through Omico Australia, a pivotal new research project focused on improving treatments for sarcoma – one of the most challenging and aggressive cancers. This initiative will help us better understand sarcoma and pave the way for more personalised, effective treatments. 

 The research will focus on three main areas:

  • Harnessing Real-World Data – Analysing information from over 1,500+ sarcoma patients who took part in Omico’s MoST and CASP initiatives. Researchers aim to evaluate current treatment efficacy, identify critical gaps in care, and explore strategies to improve patient outcomes.
  • Studying Patient Samples – By analysing biological samples from past MoST-led trials, we aim to find clues (called biomarkers) that can explain why some treatments work or don’t work. This will guide us toward better therapies in the future.
  • Targeting Proteins for Personalised Treatments –Scientists will investigate specific proteins in sarcoma patients that could be used as targets for new, precision-based therapies. This could lead to improved outcomes and a better quality of life for people with sarcoma.

Hudson Institute Sarcoma Accelerator 

Under the expert supervision of Professor Ron Firestein and Associate Professor Jason Cain, this initiative will create a comprehensive collection of tumour samples from sarcoma patients.

By leveraging cutting-edge technologies, including artificial intelligence (AI), these samples will be studied in intricate detail. The  Programme will provide a comprehensive collection of tumour samples from sarcoma patients and grown as avatar/cell-line models. These models will be studied in detail using cutting-edge technology, including artificial intelligence (AI). This approach aims to discover new, more effective treatment options tailored to each patient’s specific type of sarcoma. By understanding the unique characteristics of each tumour, we can develop targeted therapies that are more likely to be effective.

The cell line models will be comprehensively profiled in three dimensions (genomic, epigenomic, and transcriptomic) to provide both gene-specific and pathway-level analyses of sarcoma cancer models. The models and associated data developed through this initiative will form an invaluable resource, helping researchers identify and utilise appropriate sarcoma models for investigational research.

Significantly, data will be shared with the research community via our portal (vicpcc.org.au/dashboard). This publicly available database, already used in over 50 countries, will aid sarcoma research on a global scale.

This pioneering effort aims to discover new, more effective treatment options tailored to each patient’s specific type of sarcoma.

NK Cell Programme Ian Frazer Institute 

A funding collaboration by several national sarcoma not for profit organisations, supporting the work of Professor Fernando Guimaraes and his team from the Ian Frazer Institute of Translational Research in Queensland, has led to a significant step forward in the search for a cure for some of the most sinister paediatric sarcomas. The Tie Dye Project, Richies Rainbows, The Kids Cancer Project, Bricks and Smiles – the Zach Minty Project, Tour de Cure Spring Lunch, CRBF, and ANZSA supported by generous donations from Kicking Goals for Xav, Stoney’s Steps Against Sarcoma and Stop Sarcoma

Paediatric sarcomas, including rhabdomyosarcoma, Ewing sarcoma and osteosarcoma, represent a group of malignancies that significantly​ contribute to cancer-related ​illness and mortality in children and young​ adults. These cancers share common challenges, including high rates of metastasis,​ recurrence or treatment resistance, leading to a 5-year survival rate of​ approximately 20% for patients with advanced disease stages.

Despite the critical​ need, therapeutic advancements have been limited over the past three ​decades.​ The advent of chimeric antigen receptor (CAR)-based immunotherapies offers​ a promising avenue for novel treatments. However, CAR-T cells have faced significant​ challenges and limited success in treating solid tumours due to issues​ such as poor tumour infiltration​, immunosuppressive tumour microenvironments​ and off-target effects. In contrast, the adaptation of CAR technology for​ natural killer cells has demonstrated potential in both haematological ​(blood) and​ solid tumours​ (A solid tumor is a mass of solid cancer cells that grows in organ systems and can appear anywhere in the body​), suggesting a new therapeutic strategy for paediatric sarcomas​.

CCIA Sarcoma Biobank

Young Australians fighting sarcoma, an aggressive tumour that mainly affects children, teenagers, and young adults, will welcome the announcement this week of an exciting new initiative to boost vital research into this disease.

The initiative, known as the ‘Paediatric Preclinical Biobank’, has been made possible through funding of $312,000 by the Cooper Rice-Brading Foundation, which received a generous donation from the Sutcliffe Family Trust in memory of both a young family member taken by sarcoma, and of Cooper Rice-Brading, who also passed away from osteosarcoma in 2017.

Jeremy Sutcliffe, the inaugural Chairman of the Cooper Rice-Brading Foundation, said: ‘Sarcoma is a devastating cancer which disproportionately affects young people and yet is not well known and attracts insufficient funding. The Biobank is a fantastic initiative on the road to developing effective interventions and treatments which will save the lives of our youth in the future.’

The Paediatric Preclinical Biobank will be located at Children’s Cancer Institute, where researchers have developed more than 400 ‘avatar models’ — living models of disease derived from the cancer cells of children with high-risk cancers including sarcoma. These models are vital for the testing of new therapeutic approaches. The funding will support the Biobank’s flagship sarcoma program and will allow 80 unique paediatric and adolescent and young adult (AYA) sarcoma models to be characterised, expanded and made available to the research community.